Metabolic syndrome and hepatitis B treatment response
Part of Digestive system, Hormones & metabolism, Infections clinical trials.
This study looks at whether metabolic syndrome (a group of conditions like obesity, high blood pressure, and diabetes) affects how well antiviral treatment works for people with chronic hepatitis B. It may help doctors personalize treatment for people with both conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with chronic hepatitis B (a long-term liver infection).
- Your HBeAg test is positive, which may mean the virus is active and you qualify for antiviral treatment.
- You have at least 3 signs of metabolic syndrome (such as belly obesity, high blood pressure, abnormal blood fats, or high blood sugar).
- You have not taken antiviral medicine for hepatitis B in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two medicines for chronic hepatitis B: pegylated interferon and a nucleoside analogue. The goal is to see if this combo helps clear the hepatitis B surface antigen and improves the chance of a functional cure.
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
This study looks at how patients with chronic hepatitis B are managed when they visit non-liver clinics. It aims to improve care and may also include a survey about quality of life for those starting treatment.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This study tests whether a fungus-fighting drug, terbinafine, can help treat chronic hepatitis B. It is for people with stable disease who are not on other antivirals or are only on tenofovir.
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.